Сравнение

Icatibant vs. Terlipressin

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

138614-30-9

14636-12-5

Молекулярная масса

1304.52 g/mol

1227.37 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Terlipressin

Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Icatibant	Terlipressin
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Icatibant and Terlipressin?: Icatibant is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Terlipressin?: The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Terlipressin in Germany and the United States?: Германия: Icatibant — Рецептурный, Terlipressin — Рецептурный. США: Icatibant — Рецептурный, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Terlipressin

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Icatibant and Terlipressin?

Icatibant is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Terlipressin?

The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Terlipressin in Germany and the United States?

Германия: Icatibant — Рецептурный, Terlipressin — Рецептурный. США: Icatibant — Рецептурный, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.